New COPD combination drug recommended in Wales

The All Wales Medicines Strategy Group (AWMSG) has issued guidance on Relvar Ellipta 92/22mcg for use in patients with chronic obstructive pulmonary disease (COPD) within NHS Wales. This recommendation for Relvar Ellipta, which was licensed at the end of 2013 in both asthma and COPD, means health boards across Wales now have positive advice that will allow appropriate COPD patients access to the first inhaled corticosteroid and long-acting beta agonist (ICS/LABA) combination which provides continuous 24-hour efficacy in a once-daily dose. Dr Stephen McDonough, Medical Director UK, GSK: “We are delighted by this positive recommendation from the AWMSG which will